Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement

BACKGROUND: As novel systemic therapeutics for patients with atopic dermatitis (AD) are developed, ethical and methodological concerns regarding placebo‐controlled‐trials (PCT) have surfaced. OBJECTIVE: To guide the design and implementation of PCT in AD, focusing on trials with systemic medications...

Descripción completa

Detalles Bibliográficos
Autores principales: Leshem, Y.A., Bissonnette, R., Paul, C., Silverberg, J.I., Irvine, A.D., Paller, A.S., Cork, M.J., Guttman‐Yassky, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Guidelines and Position Statements
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594032/
https://www.ncbi.nlm.nih.gov/pubmed/30859656
http://dx.doi.org/10.1111/jdv.15480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594032/
https://www.ncbi.nlm.nih.gov/pubmed/30859656
http://dx.doi.org/10.1111/jdv.15480

Ejemplares similares